Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of RRMS according to the Mc Donald criteria(2005)~* 18 to 60 years of age~* Expanded Disability Status Scale (EDSS) \< 6~* Naïve subjects or subjects treated with Rebif® New Formulation for no more than 6 weeks prior to enrollment~* Subjects who have given written informed consent to participate in the study~Exclusion Criteria:~* Primary progressive or secondary progressive MS~* Subjects previously administered IFN beta-1a (including Rebif®) or IFN beta-1b or glatiramer acetate or any other immunomodulatory or immunosuppressive agents or any other MS therapy in the past with the exception of Rebif® New Formulation for no more than 6 weeks prior to enrollment~* Subjects receiving oral or systemic corticosteroids or Adrenocorticotrophic hormone within 30 days of visit 1 (prior to enrolment)~* History of any chronic pain syndrome~* Known allergy to IFN or its excipients~* Serious or acute heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure~* Inadequate liver function, defined by a alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or alkaline phosphatase \> 2 x ULN, or total bilirubin \> 2 x ULN if associated with any elevation of ALT or alkaline phosphatase~* Inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal~* Current or past (within the last 2 years) history of alcohol or drug abuse~* Contra-indications to IFN beta-1a

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).